|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001593,
umls-concept:C0005821,
umls-concept:C0014792,
umls-concept:C0175671,
umls-concept:C0243092,
umls-concept:C0449432,
umls-concept:C0450254,
umls-concept:C1179435,
umls-concept:C1524073,
umls-concept:C1548799,
umls-concept:C1705248
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-7-15
|
|
pubmed:abstractText |
Pathogen inactivation of platelet (PLT) components (INTERCEPT Blood System, Cerus Europe) was implemented into routine practice at a blood center supporting a tertiary care hospital. Utilization of platelet components (PCs) and red blood cell (RBC) components was analyzed for 3 years before and 3 years after introduction of pathogen inactivation to assess the impact of pathogen inactivation on component use.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1537-2995
|
|
pubmed:author |
pubmed-author:BoslyAndreA,
pubmed-author:CorashLaurenceL,
pubmed-author:DebryCecileC,
pubmed-author:DefoinLaurenceL,
pubmed-author:DoyenChantalC,
pubmed-author:GoffauxMaitéM,
pubmed-author:LinJin SyingJS,
pubmed-author:LinLilyL,
pubmed-author:MesseNathalieN,
pubmed-author:OsselaerJean ClaudeJC,
pubmed-author:Van HooydonkMaryseM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1412-22
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
|
|
pubmed:affiliation |
The Transfusion Center, Cliniques Universitaires de Mont Godinne, Université Catholique de Louvain, Yvoir, Belgium.
|
|
pubmed:publicationType |
Journal Article
|
